New interim data from the phase 1 assessment of investigative coronavirus 2019 (COVID-19) vaccine candidate mRNA-1273 showed the two-dose vaccine has tolerance across age groups and capability in inducing neutralizing antibodies in the upper-half range of convalescent serum across observed age strata.

The interim dose-ranging data, presented by Jacqueline M. Miller, MD, during the Advisory Committee on Immunization Practices (ACIP) August Meeting today, evidences two-dose 100mcg administration of the Moderna vaccine candidate for comprehensive pseudovirus neutralization, response titers comparable across age groups, and generally favorable tolerability and safety profiles thus far.

The phase 1 trial, sponsored by the National Institutes of Health, enrolled 120 healthy adults aged ≥18 years old. For the sake of observing immunogenicity, safety, and tolerability across age groups, participants were stratified by ages

Read More At Article Source | Article Attribution